Early dose reduction of dasatinib does not compromise clinical outcomes in patients with chronic myeloid leukemia: A comparative analysis of two prospective trials
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Shin, Dong-Yeop | - |
dc.contributor.author | Park, Sahee | - |
dc.contributor.author | Jang, Eunjung | - |
dc.contributor.author | Kong, Jee Hyun | - |
dc.contributor.author | Won, Young-Woong | - |
dc.contributor.author | Oh, Sukjoong | - |
dc.contributor.author | Choi, Yunsuk | - |
dc.contributor.author | Kim, Jeong-A | - |
dc.contributor.author | Lee, Se Won | - |
dc.contributor.author | Mun, Yeung-Chul | - |
dc.contributor.author | Kim, Hawk | - |
dc.contributor.author | Kim, Sung-Hyun | - |
dc.contributor.author | Do, Young Rok | - |
dc.contributor.author | Kwak, Jae -Yong | - |
dc.contributor.author | Kim, Hyeoung-Joon | - |
dc.contributor.author | Zang, Dae Young | - |
dc.contributor.author | Lim, Sung -Nam | - |
dc.contributor.author | Lee, Won Sik | - |
dc.contributor.author | Kim, Dong-Wook | - |
dc.date.accessioned | 2024-07-30T11:30:23Z | - |
dc.date.available | 2024-07-30T11:30:23Z | - |
dc.date.issued | 2024-08 | - |
dc.identifier.issn | 0145-2126 | - |
dc.identifier.issn | 1873-5835 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/92092 | - |
dc.description.abstract | Dasatinib is a potent second-generation tyrosine kinase inhibitor (TKI) used as a first-line treatment option for patients with chronic myeloid leukemia (CML). Currently, dose modification due to adverse events (AEs) is common in patients treated with dasatinib. This study compared the outcomes of two sequential prospective trials that enrolled patients with newly diagnosed chronic phase of CML (CP-CML) and initiated dasatinib at a starting dose of 100 mg daily. In the PCR-DEPTH study, CP-CML patients who started dasatinib 100 mg daily were enrolled and followed up, while in the DAS-CHANGE study, when patients achieved early molecular response with any grade of AEs were enrolled and treated with dasatinib 80 mg once daily. A total of 102 patients (PCR-DEPTH) and 90 patients (DAS-CHANGE) were compared. Although the median value of the relative dose intensity (RDI) of dasatinib was significantly higher in PCR-DEPTH than in DAS-CHANGE (99.6 % vs. 80.1 %, p <0.001), the MMR rate at 12months showed a trend toward superiority in DAS-CHANGE compared to PCRDEPTH (77.1 % vs 65.2 %, p = 0.084). The frequencies of MR4.0 at 24 and 36 months were higher in DASCHANGE than in PCR-DEPTH (44.4 % vs 28.8 %, p = 0.052 and 63.6 % vs 40.3 %, p= 0.013, respectively). RDIs were not different according to the MMR, MR4.0 or MR4.5 in analyses using a pooled population. Our results suggest that early dose reduction of dasatinib does not compromise efficacy in patients achieving EMR at 3 months and could be an interventional strategy for improving long term outcomes. | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | PERGAMON-ELSEVIER SCIENCE LTD | - |
dc.title | Early dose reduction of dasatinib does not compromise clinical outcomes in patients with chronic myeloid leukemia: A comparative analysis of two prospective trials | - |
dc.type | Article | - |
dc.identifier.wosid | 001261271500001 | - |
dc.identifier.doi | 10.1016/j.leukres.2024.107542 | - |
dc.identifier.bibliographicCitation | LEUKEMIA RESEARCH, v.143 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.scopusid | 2-s2.0-85196710395 | - |
dc.citation.title | LEUKEMIA RESEARCH | - |
dc.citation.volume | 143 | - |
dc.type.docType | Article | - |
dc.publisher.location | 영국 | - |
dc.subject.keywordAuthor | Chronic myeloid leukemia | - |
dc.subject.keywordAuthor | Dasatinib | - |
dc.subject.keywordAuthor | Dose modification | - |
dc.subject.keywordAuthor | Molecular response | - |
dc.subject.keywordPlus | TYROSINE KINASE INHIBITOR | - |
dc.subject.keywordPlus | 2ND-LINE DASATINIB | - |
dc.subject.keywordPlus | PLEURAL EFFUSION | - |
dc.subject.keywordPlus | IMATINIB | - |
dc.subject.keywordPlus | RESPONSES | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordPlus | SAFETY | - |
dc.subject.keywordPlus | NILOTINIB | - |
dc.subject.keywordPlus | CELLS | - |
dc.subject.keywordPlus | CML | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalResearchArea | Hematology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.relation.journalWebOfScienceCategory | Hematology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.